Description:
The Market: Pharmaceutical companies
Description:
This invention addresses the problem of developing a drug therapy for the treatment of obsessive
compulsive (OCD) spectrum disorders. Current approaches to the treatment of OCD typically
involve the use of antidepressants classically categorized as selective serotonin reuptake
inhibitors. These medications are broad acting, often not specifically approved for OCD and
often require several weeks to show efficacy.
Competitive Advantage:
This invention is novel in that it utilizes a new
approach to the treatment of OCD by targeting a novel receptor. This invention produces more
rapid and immediate effect and by selectively targeting a specific subtype of receptor, will likely
show fewer side effects.